ClinicalTrials.Veeva

Menu
H

Hospital General Universitario de Elche | Infectious Diseases Unit

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Trastuzumab
Pembrolizumab
Carboplatin
Bevacizumab
Panitumumab
Gemcitabine
Palbociclib
Irinotecan
Capecitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

36 of 177 total trials
Locations recently updated

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Active, not recruiting
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin
Locations recently updated

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling
Metastatic HER2-positive Breast Cancer
Drug: Trastuzumab
Drug: Gemcitabine

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Fulvestrant

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to...

Enrolling
Endometrial Cancer
Metastatic Cancer
Drug: Gemcitabine
Drug: ART0380

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the t...

Active, not recruiting
Metastatic Colorectal Cancer
Biological: Pembrolizumab
Biological: Cetuximab

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in c...

Active, not recruiting
HER2+/HR+ Breast Cancer
Drug: ZW25 (Zanidatamab)
Drug: Fulvestrant

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab...

Active, not recruiting
Parkinsons Disease
Drug: Placebo
Drug: Prasinezumab

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozo...

Enrolling
Breast Cancer
Drug: PF-07220060
Drug: letrozole

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-d...

Active, not recruiting
Gastro-enteropancreatic Neuroendocrine Tumor
Drug: CAM2029
Drug: Lanreotide ATG

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting
Parkinson's Disease (PD)
Drug: ABBV-951

People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretrovir...

Enrolling
HIV-1 Infected Adults with Controlled Viremia
Drug: Cabotegravir LA + Rilpivirine LA

Trial sponsors

Pfizer logo
S
Roche logo
Gilead Sciences logo
F
G
G
H
S
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems